Belimumab denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Belimumab as Non-Formulary

Belimumab is a specialty biologic whose formulary status varies across UnitedHealthcare plan types and contract years. A non-formulary denial means your specific plan either does not list belimumab on its covered drug tier or places it at a tier that requires prior authorization or a formulary exception before coverage is available. This is a plan-design issue — not a clinical judgment that belimumab is inappropriate — and it is one of the most commonly reversed denial types.

## Why This Denial Is Appealable

Federal rules require health plans to cover non-formulary drugs when no formulary alternative is medically adequate for a given patient's condition. For belimumab, with its specific mechanism targeting BLyS, a prescriber can document that formulary-listed alternatives do not offer the same clinical approach and that switching would be clinically inappropriate. A formulary exception request, supported by strong physician documentation, is the fastest path to coverage.

## Federal Appeal Framework

• ACA §2719 external review: Available after internal appeal is exhausted. File within approximately four months of denial — confirm the exact deadline on your EOB. IROs regularly grant formulary exceptions when the clinical rationale for the specific drug is well documented.
• ERISA §503: Employer-plan members are entitled to the plan's formulary-exception criteria and full-and-fair review.
• Expedited review: Available when SLE disease activity is serious and delay in starting belimumab poses a genuine health risk.

## Concrete Appeal Steps

1. Request the UHC formulary for your plan year and identify which SLE biologics or immunosuppressants are on the covered tiers. 2. Obtain UHC's formulary-exception criteria for specialty drugs. 3. For each formulary-listed alternative, have the rheumatologist document why it is not appropriate for this patient (different mechanism, prior failure, intolerance, or clinical contraindication per the physician's assessment). 4. Submit a formulary-exception request and a formal internal appeal together. 5. If denied, escalate to external IRO review.

## Documentation to Gather

• SLE diagnosis and autoantibody status: confirms the patient has the condition for which belimumab is FDA-approved.
• Formulary-alternative assessment: for each drug on the covered tier that UHC might consider a substitute, a chart note or physician letter explaining why it is clinically inadequate for this patient.
• Prior-treatment history: names, dates, and outcomes for any SLE therapies previously tried, establishing the treatment journey that led to belimumab.
• Prescriber formulary-exception letter: explains belimumab's distinct mechanism, the inadequacy of alternatives for this specific patient, and references the FDA-approved prescribing label and the applicable ACR guideline organization.

## Criteria-Mapping Structure

Obtain UHC's formulary-exception policy and list every criterion. For each criterion, identify the chart document and clinical fact that satisfies it. Pay particular attention to any criterion requiring documentation that formulary alternatives were tried and failed or are clinically inappropriate — this is typically the decisive element in a non-formulary exception appeal.